336 related articles for article (PubMed ID: 11549514)
21. [Cancer and immunosuppression : experimental aspects].
Maral J; Florentin I; Soubrane C; Maral R
Bull Cancer; 1983; 70(5):351-71. PubMed ID: 6230125
[TBL] [Abstract][Full Text] [Related]
22. [Cytotoxic T lymphocytes: role in immunosurveillance and in immunotherapy].
Benchetrit F; Gazagne A; Adotevi O; Haicheur N; Godard B; Badoual C; Fridman WH; Tartour E
Bull Cancer; 2003; 90(8-9):677-85. PubMed ID: 14609756
[TBL] [Abstract][Full Text] [Related]
23. Tumors and the danger model.
Kowalczyk DW
Acta Biochim Pol; 2002; 49(2):295-302. PubMed ID: 12362970
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of immune escape of cancer and its regulation.
Morita R; Hirohashi Y; Torigoe T
Rinsho Ketsueki; 2009 May; 50(5):375-80. PubMed ID: 19483397
[No Abstract] [Full Text] [Related]
25. Mechanisms of local immunoresistance in glioma.
Albesiano E; Han JE; Lim M
Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963
[TBL] [Abstract][Full Text] [Related]
26. Tumor dormancy and immunoescape.
Quesnel B
APMIS; 2008; 116(7-8):685-94. PubMed ID: 18834412
[TBL] [Abstract][Full Text] [Related]
27. HLA-G and its KIR ligands in cancer--another enigma yet to be solved?
Urosevic M; Trojan A; Dummer R
J Pathol; 2002 Mar; 196(3):252-3. PubMed ID: 11857486
[TBL] [Abstract][Full Text] [Related]
28. Immunosurveillance and immunoediting--can the immune response be made more "immunodemocratic"?
Mincheff M
J BUON; 2009 Sep; 14 Suppl 1():S89-96. PubMed ID: 19785075
[TBL] [Abstract][Full Text] [Related]
29. Harnessing the immune response to treat cancer.
Steer HJ; Lake RA; Nowak AK; Robinson BW
Oncogene; 2010 Dec; 29(48):6301-13. PubMed ID: 20856204
[TBL] [Abstract][Full Text] [Related]
30. The immune system--is it relevant to cancer development, progression and treatment?
Prestwich RJ; Errington F; Hatfield P; Merrick AE; Ilett EJ; Selby PJ; Melcher AA
Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):101-12. PubMed ID: 18037277
[TBL] [Abstract][Full Text] [Related]
31. Tumor immunosuppressive environment: effects on tumor-specific and nontumor antigen immune responses.
de Souza AP; Bonorino C
Expert Rev Anticancer Ther; 2009 Sep; 9(9):1317-32. PubMed ID: 19761435
[TBL] [Abstract][Full Text] [Related]
32. Escape from immune- and nonimmune-mediated tumor surveillance.
Malmberg KJ; Ljunggren HG
Semin Cancer Biol; 2006 Feb; 16(1):16-31. PubMed ID: 16140546
[TBL] [Abstract][Full Text] [Related]
33. Cancer and immune response: old and new evidence for future challenges.
de la Cruz-Merino L; Grande-Pulido E; Albero-Tamarit A; Codes-Manuel de Villena ME
Oncologist; 2008 Dec; 13(12):1246-54. PubMed ID: 19056856
[TBL] [Abstract][Full Text] [Related]
34. Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system.
Mocarski ES
Cell Microbiol; 2004 Aug; 6(8):707-17. PubMed ID: 15236638
[TBL] [Abstract][Full Text] [Related]
35. The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma.
Wang E; Selleri S; Marincola FM
Clin Cancer Res; 2007 Dec; 13(24):7228-31. PubMed ID: 18094399
[No Abstract] [Full Text] [Related]
36. [Immune tolerance and active suppression in oncology. Immunological principles and therapeutic options].
Stremmel C; Klein P; Hohenberger W
Chirurg; 2002 Mar; 73(3):255-61. PubMed ID: 11963500
[TBL] [Abstract][Full Text] [Related]
37. Immunology. Stress, NK receptors, and immune surveillance.
Pardoll DM
Science; 2001 Oct; 294(5542):534-6. PubMed ID: 11567108
[No Abstract] [Full Text] [Related]
38. Tumor escape from killing: role of killer inhibitory receptors and acquisition of tumor resistance to cell death.
Chouaib S; Thiery J; Gati A; Guerra N; El Behi M; Dorothée G; Mami-Chouaib F; Bellet D; Caignard A
Tissue Antigens; 2002 Oct; 60(4):273-81. PubMed ID: 12472656
[TBL] [Abstract][Full Text] [Related]
39. Metastatic spread and "escape" from the immune defenses of the host.
Alexander P
Natl Cancer Inst Monogr; 1976 Nov; 44():125-9. PubMed ID: 1025472
[TBL] [Abstract][Full Text] [Related]
40. Immature myeloid cells and cancer-associated immune suppression.
Kusmartsev S; Gabrilovich DI
Cancer Immunol Immunother; 2002 Aug; 51(6):293-8. PubMed ID: 12111117
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
